Cargando…
Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models
SARS-CoV-2 is the coronavirus that causes the respiratory disease COVID-19, which is now the third-leading cause of death in the United States. The FDA has recently approved remdesivir, an inhibitor of SARS-CoV-2 replication, to treat COVID-19, though recent data from the WHO shows little to no bene...
Autores principales: | Li, Xiaoquan, Lidsky, Peter, Xiao, Yinghong, Wu, Chien-Ting, GarciaKnight, Miguel, Yang, Junjiao, Nakayama, Tsuguhisa, Nayak, Jayakar V., Jackson, Peter K., Andino, Raul, Shu, Xiaokun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605555/ https://www.ncbi.nlm.nih.gov/pubmed/33140048 http://dx.doi.org/10.1101/2020.10.28.359042 |
Ejemplares similares
-
Ethacridine inhibits SARS-CoV-2 by inactivating viral particles
por: Li, Xiaoquan, et al.
Publicado: (2021) -
Spectrophotometric determination of ethacridine lactate in infusion
por: Jain, Pritam S., et al.
Publicado: (2011) -
Variability in viral pathogenesis: modeling the dynamic of acute and persistent infections
por: Lidsky, Peter V, et al.
Publicado: (2017) -
SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming
por: Wu, Chien-Ting, et al.
Publicado: (2023) -
SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment
por: Wu, Chien-Ting, et al.
Publicado: (2021)